Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]

首页> 外文期刊>ClinicoEconomics and Outcomes Research >Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]

【24h】

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]

机译：基于系统性调查，意大利17家医院的非霍奇金淋巴瘤皮下注射和静脉注射利妥昔单抗和乳腺癌曲妥珠单抗的潜在资源和成本节省分析[勘误]

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《ClinicoEconomics and Outcomes Research》 |2017年第10期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献

1. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [J] . Clemente Ponzetti, Monica Canciani, Massimo Farina, ClinicoEconomics and Outcomes Research . 2016,第67期

机译：基于系统性调查，在意大利的17家医院中，皮下注射和静脉注射利妥昔单抗治疗非霍奇金淋巴瘤和曲妥珠单抗治疗乳腺癌的潜在资源和成本节省分析
2. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands [J] . Margreet G. Franken, Tim A. Kanters, Jules L. Coenen, Anti-cancer drugs . 2018,第8期

机译：由于肿瘤药物施用途径的潜在成本：荷兰静脉和皮下施用曲妥珠单抗和拉特昔单抗的微观研究
3. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit [J] . Wiebren A.A. Tjalma, Tom Van den Mooter, Tim Mertens, European Journal of Obstetrics, Gynecology and Reproductive Biology: An International Journal . 2018,第期

机译：皮下曲据（Herceptin）与静脉内曲妥珠单抗治疗Her2阳性乳腺癌的患者：瘦营运日保健肿瘤学单位的时间，运动和成本评估研究
4. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
5. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey Corrigendum [O] . 2017

机译：基于系统调查皮下注射或静脉注射利妥昔单抗治疗非霍奇金淋巴瘤和曲妥珠单抗治疗乳腺癌的潜在资源和成本分析在意大利的17家医院中更正
6. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkinrsquo;s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey Corrigendum [O] . Clemente Ponzetti, Monica Canciani, Massimo Farina, 2017

机译：基于系统调查的17名意大利医院在非霍奇金淋巴瘤中皮下与静脉内泌尿外静脉静脉静脉施用的潜在资源和成本节约分析。基于系统调查勘误

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]

著录项

相似文献

相关主题

期刊订阅